Buscar
Mostrando ítems 41-50 de 67
Persistent Pulmonary Hypertension in Corrected Valvular Heart Disease: Hemodynamic Insights and Long‐Term Survival
(Willey, 2021-01-19)
[Abstract]
Background. The determinants and consequences of pulmonary hypertension after successfully corrected valvular heart disease remain poorly understood. We aim to clarify the hemodynamic bases and risk factors for ...
2019 EACTS Expert Consensus on long-term mechanical circulatory support
(Oxford, 2019-05-17)
[Abstract] Long-term mechanical circulatory support (LT-MCS) is an important treatment modality for patients with severe heart failure. Different devices are available, and many—sometimes contradictory—observations regarding ...
Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: GALACTIC‐HF Baseline Characteristics and Comparison With Contemporary Clinical Trials
(Willey Online Library, 2020-09-20)
[Abstract]
Aims
The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is being tested in the Global Approach ...
Emery–Dreifuss muscular dystrophy Type 1 is associated with a high risk of malignant ventricular arrhythmias and end-stage heart failure
(Oxford Academic, 2023-08-28)
[Abstract] Emery–Dreifuss muscular dystrophy (EDMD) is caused by variants in EMD (EDMD1) and LMNA (EDMD2). Cardiac conduction defects and atrial arrhythmia are common to both, but LMNA variants also cause end-stage heart ...
Fifteen-year differences in indications for cardiac resynchronization therapy in international guidelines—insights from the heart failure registries of the European Society of Cardiology
(MDPI, 2022-06-06)
[Abstract] Cardiac resynchronization therapy (CRT) applied to selected patients with heart failure (HF) improves their prognosis. In recent years, eligibility criteria for CRT have regularly changed. This study aimed to ...
Extracellular Matrix in Heart Failure: Role of ADAMTS5 in Proteoglycan Remodeling
(American Heart Association, 2021-11-22)
[Abstract] Background: Remodeling of the extracellular matrix (ECM) is a hallmark of heart failure (HF). Our previous analysis of the secretome of murine cardiac fibroblasts returned ADAMTS5 (a disintegrin and metalloproteinase ...
Prevalence, characteristics and prognostic impact of aortic valve disease in patients with heart failure and reduced, mildly reduced, and preserved ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry
(Wiley, 2023-05-21)
[Abstract] Aims: To assess the prevalence, clinical characteristics, and outcomes of patients with heart failure (HF) with or without moderate to severe aortic valve disease (AVD) (aortic stenosis [AS], aortic regurgitation ...
Adherence to the ESC heart failure treatment guidelines in Spain: ESC Heart Failure Long-term Registry
(Elsevier para Sociedad Española de Cardiología, 2015-05-21)
[Abstract] Introduction and objectives. To estimate the percentage of heart failure patients in Spain that received the European Society of Cardiology recommended treatments, and in those that did not, to determine the ...
Assessment of omecamtiv mecarbil for the treatment of patients with severe heart failure: a post hoc analysis of data from the GALACTIC-HF randomized clinical trial
(American Medical Association, 2021-10-13)
[Abstract] Importance: Heart failure with reduced ejection fraction is a progressive clinical syndrome, and many patients' condition worsen over time despite treatment. Patients with more severe disease are often intolerant ...
Sex differences in heart failure with reduced ejection fraction in the GALACTIC-HF trial
(Elsevier on behalf of the American College of Cardiology Foundation, 2023-10-11)
[Abstract] Background: Women with heart failure with reduced ejection fraction (HFrEF) receive less guideline-recommended therapy and experience worse quality of life than men.
Objectives: The authors sought to assess ...